HALOZYME THERAPEUTICS, INC. Stock Repurchase Program, Authorized Amount
HALOZYME THERAPEUTICS, INC. (HALO) had Stock Repurchase Program, Authorized Amount of $750.00 million as of 2021-12-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2024-05-07
- 2021-12-31: Stock Repurchase Program, Authorized Amount $750.00M.
- 2019-11-30: Stock Repurchase Program, Authorized Amount $550.00M.
| Period end | Stock Repurchase Program, Authorized Amount |
|---|---|
| 2021-12-31 | $750.00M 10-Q · filed 2024-05-07 |
| 2019-11-30 | $550.00M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |